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Abstract
Background: Xenograft mouse models represent helpful tools for preclinical studies on human tumors. For modeling the
complexity of the human disease, primary tumor cells are by far superior to established cell lines. As qualified exemplary
model, patients’ acute lymphoblastic leukemia cells reliably engraft in mice inducing orthotopic disseminated leukemia
closely resembling the disease in men. Unfortunately, disease monitoring of acute lymphoblastic leukemia in mice is
hampered by lack of a suitable readout parameter.
Design and Methods: Patients’ acute lymphoblastic leukemia cells were lentivirally transduced to express the membrane-
bound form of Gaussia luciferase. In vivo imaging was established in individual patients’ leukemias and extensively
validated.
Results: Bioluminescence in vivo imaging enabled reliable and continuous follow-up of individual mice. Light emission
strictly correlated to post mortem quantification of leukemic burden and revealed a logarithmic, time and cell number
dependent growth pattern. Imaging conveniently quantified frequencies of leukemia initiating cells in limiting dilution
transplantation assays. Upon detecting a single leukemia cell within more than 10,000 bone marrow cells, imaging enabled
monitoring minimal residual disease, time to tumor re-growth and relapse. Imaging quantified therapy effects precisely and
with low variances, discriminating treatment failure from partial and complete responses.
Conclusions: For the first time, we characterized in detail how in vivo imaging reforms preclinical studies on patient-derived
tumors upon increasing monitoring resolution. In the future, in vivo imaging will enable performing precise preclinical
studies on a broad range of highly demanding clinical challenges, such as treatment failure, resistance in leukemia initiating
cells, minimal residual disease and relapse.
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Introduction
Preclinical mouse models are helpful tools for studying biology
and therapy of diseases. Novel therapeutic approaches undergo
detailed preclinical evaluation before translation into clinical trials
[1]. In the present work, a defined preclinical leukemia mouse
model was technically improved to allow decisive studies on
clinically demanding challenges.
In cancer research, a variety of different mouse models exist
including xenotransplantation models and syngeneic models [2].
Xenotransplantation models enable studying human tumor cells
upon growth in severely immunocompromised mice [3]. Within
the xenotransplantation models, the use of primary patients’ tumor
cells is superior to the use of cell lines, as primary cells enable
modeling of the complex heterogeneity of human tumors, while
cell lines might have acquired non-physiologic mutations upon
prolonged culture in vitro [4].
At best, xenotransplanted tumor cells generate a disease in mice
which highly resembles the disease in men [5]. Nevertheless,
transplantation of solid tumors might suffer from heterotopic
tumor localization and metastasis in mice [5]. In contrast, tumor
cells obtained from patients with acute lymphoblastic leukemia
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(ALL) engraft and develop the disease in mice with an organ
distribution highly similar between mice and men [6]. In fact,
since 2 decades the xenotransplantation model of patient ALL cells
is well characterized [7] and fulfills many criteria requested for
preclinical treatment trials. Due to high engraftment rates, the
heterogeneity of ALL can be modeled in mice and trials are
performed in genetically defined subgroups of ALLs [6]. Neverthe-
less, first engraftment in mice might be non-representative for the
heterogeneity of the human sample [8] and clonal evolution might
take place upon passaging cells through mice, although reportedly
at a minor level [9]. Taken together, xenotransplantation of
primary human ALL into mice emerges as attractive model for
preclinical anti-cancer trials in general.
Nevertheless, sensitive follow up of leukemia progression in mice
remains a limitation of the model. Invasive bone marrow
aspirations in mice require prolonged periods of recuperation;
blood sampling is hampered by late and heterogeneous presence of
tumor cells into the peripheral blood [10]. Lack of sensitive and
convenient follow up of the leukemic disease so far disabled
quantifying treatment responses and differentiating distinct clinical
disease stages.
In vivo imaging based on molecular cell marking represents
a sensitive readout parameter to monitor xenotransplanted tumors
in mice, e.g., using bioluminescence [11,12]. So far, in vivo
imaging was mainly performed in preclinical models using tumor
cell lines as patient-derived tumor cells are more difficult in
handling, e.g., for molecular manipulation. Patient-derived tumor
cells do not grow in vitro; instead, they survive only few hours in
culture.
Here, we established the molecular labeling of patient-derived
ALL cells and characterized in detail, how bioluminescence
in vivo imaging enables a novel level of precision for future
preclinical studies. In vivo imaging enabled quantification of
treatment effects and monitoring of minimal residual disease in
mice. The improved mouse model will allow performing decisive
and complex preclinical studies on individual leukemias in the
future.
Design and Methods
Ethical Statements
Written informed consent was obtained from all patients and
from parents/carers in the cases where patients were minors. The
study was performed in accordance with the ethical standards of
the responsible committee on human experimentation (written
approval by Ethikkommission des Klinikums der Ludwig-
Maximilians-Universita¨t Mu¨nchen, Ethikkommission@med.uni-
muenchen.de, April 15/2008, number 068-08) and with the
Helsinki Declaration of 1975, as revised in 2000.
All animal trials were performed in accordance with the current
ethical standards of the official committee on animal experimen-
tation (written approval by Regierung von Oberbayern,
poststelle@reg-ob.bayern.de, May 10/2007, number 55.2-1-54-
2531-2-07).
Cloning and Production of Lentiviruses
The GLuc construct encoding for the human CD8 leader
peptide and the CD8 transmembrane domain fused to GLuc [13]
was subcloned into the multicloning site of pCDH-EF1-MCS-
T2A-copGFP vector (System Biosciences, Mountain View, CA,
USA) using EcoRI and BamHI. The 39 stop codon was removed
during PCR amplification.
The third generation packaging plasmids pMDLg/pRRE,
pRSV-Rev and pMD2-G [14] were kindly provided by T.
Schroeder. High-titer vesicular stomatitis virus (VSV) G protein-
pseudotyped lentivector was prepared by transient four-plasmid
transfection of 293T cells using Trans-ITH-293 Transfection
Reagent (Mirus, Madison, WI, USA) and supernatant concentra-
tion as described [15]. The functional titer of virus was determined
by infection of 293T cells with serial dilutions of the vector stock,
followed by cytometric analysis of GFP positive cells. Viral titer
was set to 56108 transduction units/ml.
Generation of GLuc Expressing Patient-derived ALL Cells
Patient-derived leukemia cells were freshly isolated from mouse
spleens, purified and cultured in RPMI medium supplemented
with 20% FCS, 1% penicillin/streptomycin, 1% gentamycin,
6 ml/ml mixture of insulin, transferrin and selenium (Invitrogen,
Carlsbad, CA), 1 mM sodium pyruvate and 50 mM 1-thioglycer-
ole (Sigma-Aldrich, St. Louis, MO) in the absence of further
cytokines as described [16,17]. Cells were transduced overnight
with GLuc virus in the additional presence of 3 mg/ml polybrene
(Sigma, Hamburg, Germany). After extensive washing in phos-
phate-buffered saline (PBS) plus 2% FCS to remove vivid virus, 1–
3 million cells per mouse were injected intravenously into recipient
NSG (NOD-scid IL2Rgammanull, The Jackson Laboratory, Bar
Harbour, ME, USA) mice for amplification. After passaging, cells
were sorted using the FACSVantage SE machine (BD Biosciences)
and re-amplified in mice. For samples ALL-4S and ALL-50 cell
sorting was repeated once after re-passaging through mice.
Bioluminescence in vivo Imaging
The IVIS Lumina II Imaging System was used (Caliper Life
Sciences, Mainz, Germany). Mice were anesthetized using
isoflurane, placed into the imaging chamber in a supine position
and fixed at the lower limbs and by the inhalation tube.
Coelenterazine (Synchem OHG, Felsberg/Altenburg, Germany)
was dissolved in acidified methanol (HPLC grade) at concentration
10 mg/ml and diluted shortly before injection in sterile HBG
buffer (HEPES-buffered Glucose containing 20 mM HEPES at
pH 7.1, 5% glucose w/v). Immediately after intravenous tail vein
injection of 100 mg of native Coelenterazine, mice were imaged for
15 seconds using a field of view of 12,5 cm with binning 8, f/stop 1
and open filter setting. To monitor tumor growth, mice were
imaged once weekly; after therapy, mice were imaged every other
day.
Quantification of Imaging Pictures
The Living Image software 4.x (Caliper Life Sciences, Mainz,
Germany) was used for data acquisition and quantification of light
emission using a scale with a minimum of 1,86104 photons per
second per cm2 per solid angle of one steradian (sr). Different
regions of interest (ROI) were defined and signals were considered
positive, when light emission exceeded background in each ROI;
background was measured in 15 mice harboring GLuc negative
leukemias; a ROI covering the entire animal was used (back-
ground 46106 photons per second); as an exception and to
determine early engraftment =minimal disease, a small ROI
(0,35 cm2; background 66104 photons per second) was set at
femurs at the location, where and when first light emission became
visible; depending on the expression level of the transgenes, overt
leukemia was considered above 109–1010 photons per second
using the ROI covering the entire animal; overt leukemia served as
criterion for ending experiments, as it shortly preceded onset of
clinical signs of disease in mice.
In Vivo Imaging of Patients’ ALLs in Mice
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Preclinical in vivo Treatment Trials
Control animals received physiological salt solution intraperito-
neally; treatment group mice were injected i.p. with a single dose
of either Etoposid (VP-16; 50 mg/kg; Sigma, Hamburg, Ger-
many) or Cyclophosphamide (Cyclo; 150 mg/kg; Baxter, Unters-
chleissheim, Germany) diluted in 0.9% NaCl.
Statistical Analysis
Mean and standard error of the mean (SEM) were calculated
using the Microsoft Excel 2010 software (Microsoft, Redmont,
WA, USA). To determine significance of treatment effects in vivo,
Mann-Whitney Rank Sum Test and the Sigma Plot 12 software
(Systat Software, Erkrath, Germany) was used. CSC frequencies
were calculated according to Poisson statistics using the ELDA
software application (http://bioinf.wehi.edu.au/software/elda).
Additional Methods
See Supporting Information S1 for description on the animal
model, LDTA, qRT-PCR, flow cytometry, histology and in vitro
apoptosis assays.
Results
The aim was to introduce and validate in vivo imaging as novel
readout parameter for monitoring patient-derived leukemias
growing in mice. Sensitive and reliable disease monitoring will
allow decisive preclinical studies on a novel level of complexity and
accuracy in the future.
Generation of Gaussia Luciferase-expressing Patient-
derived ALL Cells
To establish in vivo imaging as readout for monitoring in-
dividual ALLs in mice, Gaussia luciferase (GLuc) was chosen in its
membrane-bound form [13]. GLuc emits highly intensive light
compared to luciferases of other species and is especially useful in
monitoring superficial organs such as bone marrow [18].
Leukemia cells are notoriously difficult to transfect and patient-
derived leukemia cells do not allow antibiotics-based selection
in vitro. Therefore, lentiviral transduction was chosen, although
transgene integration into unsuitable genomic sites might alter cell
function. GLuc was cloned into a lentiviral vector harboring
additionally copepod green fluorescence protein (GFP) (Figure 1a).
Primary ALL cells were passaged through mice at least once. Cells
freshly isolated from mouse spleens were transduced overnight
using a multitude of infection of 30–100 lentiviruses per cell in the
presence of 3 mg/ml polybrene without further addition of
cytokines. Next morning and after extensive washing in phos-
phate-buffered saline (PBS) plus 2% FCS to remove vivid virus, 1–
3 million cells per mouse were injected intravenously into recipient
NSG (NOD-scid IL2Rgammanull, The Jackson Laboratory, Bar
Harbour, ME, USA) mice for amplification. After passaging, cells
were sorted using the FACSVantage SE machine (BD Biosciences)
and re-amplified in mice. For samples ALL-4S and ALL-50 cell
sorting was repeated once after re-passaging through mice.
All 9 samples from children with ALL (1 T-ALL and 8 B-ALL,
clinical data in Supplemental Table 1) were successfully trans-
duced, although transduction efficiencies and levels of transgene
expression varied widely between samples (Figure 1b and 1c).
While high transduction rates ensured molecular staining of
representative cells, low transduction rates contained the risk of
selecting non-representative cells. Transduced cells were enriched
by 1 or 2 rounds of cell sorting using GFP to above 90% in all
samples (data not shown); transgene expression remained stable
over passaging suggesting successful transduction of leukemia
initiating cells (Supplemental Table 2). Transduction and expres-
sion of transgenes did not alter important functional biological
characteristics of patient-derived ALL cells, not even after various
rounds of passaging through mice (Figure 1d, Supplemental
Figure 1). For details please refer to the suppl. Results section.
Taken together, lentiviral transduction enabled generating patient-
derived ALL cells expressing transgenes without altering the
described basic biological cell characteristics studied. In the future
and using transgenes other than marker genes, the technique will
enable molecular signaling studies in patient-derived leukemia
cells.
In vivo Imaging of Patient-derived ALL in Mice
For imaging, the convenient IVIS Lumina II Imaging System
(Caliper Life Sciences) was used together with an optimized
protocol (for details see suppl. Results). Kinetics of GLuc-emitted
light from leukemia cells was similar to published kinetics on
GLuc-expressing T-cells [13] (Supplemental Figure 2). Injection of
Coelenterazine resulted in a substrate-related light emission from
the liver independently from the presence of GLuc in all mice; in
non-leukemic control mice (data not shown), in mice bearing
a non-transgenic leukemia (Supplemental Figure 3a) or in mice
bearing leukemia transgenic only for expression of GFP, but not
GLuc (Supplemental Figure 3b). The unspecific liver signal did not
interfere with evaluation of the leukemic disease as it was of minor
intensity. The imaging procedure was performed easily in
handling and well tolerated by all mice with a nearly absent
imaging-related death rate restricted to mice with highly advanced
leukemia.
Bioluminescence in vivo imaging using GLuc visualized en-
graftment of patient-derived ALL cells in mice first in the lower
extremities where bones and bone marrow are located directly
under the fur (Figure 2a). Over time, other bones such as sternum
and jaw bones emitted light. Only at a late stage of disease, inner
organs like spleen became visible. Leukemia-specific liver signals
were 1 or 2 orders of magnitude more intensive compared to the
unspecific, substrate-specific liver signal. Thus, GLuc-based
in vivo imaging enabled the detailed monitoring of single animals
over time.
Likewise, light emission strongly depended on the number of
cells injected, indicating that both kinetic and dose response were
clearly represented by in vivo imaging in this model (Figure 2b).
The growth pattern of leukemia in mice was highly similar
between the samples of different ALL patients and independent
from the subtype of ALL or clinical parameters (Supplemental
Figure 4, Supplemental Table 1). Expression of transgenes was
restricted to human leukemia cells sparing mouse recipient cells as
all GFP-expressing cells were positive for expression of human
leukemia-specific antigens such as CD38 and CD45 (Supplemen-
tal Figure 5 and data not shown).
To reassure that imaging reliably visualized the leukemic
disease, in vivo imaging data were correlated to conventional post
mortem readouts. Single mice engrafted with sample ALL-50 were
sacrificed weekly and bone marrow and spleen were analyzed by
flow cytometry and immunohistochemistry to quantify leukemic
cells. Imaging was more sensitive in detecting leukemic infiltration
in bone marrow than in spleen arguing towards the highest
sensitivity of imaging in visualizing ALL in bone marrow located
directly under the fur (Figure 2c and Supplemental Figure 6;
similar data not shown for sample ALL-4S, ALL-177 and ALL-
199). Light emission correlated well to leukemic infiltration of
bone marrow as measured post mortem by FACs analysis
(correlation coefficient of 0,86; Figure 2d), but was unable to
reliably detect leukemic infiltration in spleens (correlation co-
In Vivo Imaging of Patients’ ALLs in Mice
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efficient of 0,65; Supplemental Figure 6). At late stages of leukemia
disease, imaging revealed a diffuse leukemic infiltration through-
out the entire mouse body which was paralleled by GLuc-based
light emission from isolated organs such as bones, spleen, liver,
peripheral blood, lungs and brain (Supplemental Figure 7). Taken
together, imaging precisely visualized the clinical course of
leukemia in single mice over time with good correlation to
conventional post mortem readout parameters.
Quantification, Logarithmic Growth and Quality
Parameters
To quantify light emission, regions of interest were defined and
analyzed using the Living Image software 4.0 (Caliper Life
Sciences). In close correlation to the visual impression, quantifi-
cation revealed first engraftment in a region covering the lower
extremities, while inner organs became visible at late time points
followed by extremely rapid signal increase (Figure 3a). For further
Figure 1. Generation of GLuc -expressing patient-derived ALL cells. a Scheme of the lentiviral vector construct; arrow indicates start of
transcription; RSV/59LTR= hybrid of the Rous Sarcoma virus promoter and the U5 long terminal repeat from HIV-1 virus; EF1 P = constitutive
elongation factor 1-alpha promoter; GLuc =membrane anchored form of the Gaussia luciferase (GLuc) enzyme fused to the transmembrane domain
of CD8; T2A= ‘‘self-cleaving’’ 2A peptide from insect virus Thosea asigna; copGFP=green fluorescent protein cloned from copepod Pontellina
plumata; 39DLTR=HIV-1 virus long terminal repeat with a self-inactivating U3 deletion; b, cTransduction efficiency as determined by flow cytometry
measurement of GFP expression after one round of amplification of transduced cells in mice; (b) in ALL-50 and ALL-199; (c) in all 9 patient-derived
ALL samples studied; d Stability of biological characteristics of patient-derived ALL cells despite of lentiviral transduction; examples from data shown
in detail in Supplemental Figure 1; comparison of ALL-199 cells before and after lentiviral transduction and sorting concerning drug-induced cell
death after 48 hours in vitro (left panel), expression of cell surface markers (middle panel) and time to engraftment (right panel).
doi:10.1371/journal.pone.0052798.g001
Figure 2. In vivo imaging of patient-derived ALL in mice. a Kinetics of leukemic growth; 56104 ALL-177 cells per mouse were injected into
a group of 5 mice which were imaged repeatedly over time; a single representative mouse is shown; units in rainbow color scales are photons per
second per cm2 per steradian (photons s21 cm221 sr21); b Dose-response of leukemic growth; 16107–36104 serially diluted ALL-177 cells were
injected into groups of 5 mice which were imaged 8 weeks after injection; a single representative mouse is shown for each group; c, dGood
correlation of in vivo imaging to post mortem readout parameters; 12 mice were injected with 105 ALL-50 cells/mouse; each week, 2 mice were
imaged and sacrificed; organs were collected and cell suspensions prepared from half the organ and 1 femur and were analyzed by flow cytometry
for expression of GFP/human CD38; the other half of the organ and the second femur were analyzed by immunohistochemistry for expression of
terminal desoxynucleotidyl transferase (Tdt; arrows indicate leukemia cells); rare, +, ++,+++indicate a rough quantification of the number of leukemic
cells per field; c shows 1 representative image per week and post mortem analysis of bone marrow; in all mice, mid-abdominal signals are unspecific.
d correlates results from imaging and FACs analysis in each mouse; correlation coefficient 0,86; Supplemental Figure 6 shows data on spleens.
doi:10.1371/journal.pone.0052798.g002
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studies, light emission of the entire animals was quantified as it
represented the most reliable average value.
Quantification of light emission revealed a strictly logarithmic
growth of patient-derived leukemia cells in mice covering up to 4
orders of magnitude (Figure 3a). Similarly, the relation between
cell number injected and light emission was logarithmic
(Figure 3b).
Individual leukemias were obtained from patients with very
different clinical parameters, including primary disease and
relapse, and contained completely different cytogenetic and
molecular alterations (Supplemental Table 1). Light emission
Figure 3. Quantification, quality parameters and visualization of minimal disease. a Procedure of quantification; images of the
representative mouse shown in Figure 2a were quantified over time; 3 different regions were analyzed which are indicated with red squares in the
image: (i) sum of 2 regions at the lower extremities (legs); (ii) part of the abdomen (spleen); (iii) the whole mouse body (entire mouse); b Logarithmic
relation between cell number injected and light emission; all mice described in Figure 2b were imaged after 10 weeks and images were quantified;
shown is the mean +/2 standard error of the mean (SEM); c Imaging reveals logarithmic growth over time and low assay variances; 56104 ALL-177
cells per mouse were injected into groups of 5 mice each in two independent experiments performed 2 months apart; mice were imaged repetitively
over time and images quantified; shown is the mean of each group +/2 SEM; d Imaging enables monitoring minimal disease; ALL-4S, ALL-177 (56104
cells/mouse) or ALL-199 (16104 cells/mouse) with expression level of GFP as indicated (middle panel, mean fluorescence intensity - MFI) were
injected into 7 mice per group; engraftment was considered positive at light emission above 66104 photons per second in the ROI indicated (see
Methods for details) (upper panel shows one representative mouse); 4 of 7 mice were sacrificed and analyzed; shown are the frequencies of leukemia
cells in bone marrow as determined by quantitative real time polymerase chain reaction (qRT-PCR) as mean per group of mice; see also Supplemental
Figure 10. In all mice, mid-abdominal signals are unspecific.
doi:10.1371/journal.pone.0052798.g003
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quantification of ALL samples showed that all samples grew in
a logarithmic pattern in mice (Supplemental Figure 8 and data not
shown). Thus, logarithmic growth appears as general principle
how human leukemia cells behave in mice. Nevertheless and
Figure 4. Imaging-based quantification of leukemia initiating cell frequencies. a Imaging visualizes dependence of leukemic growth on
both time and cell numbers; experiment shown in Figure 2b was followed up over time in all groups injected with the different cell numbers;
depicted is the quantification of imaging as mean of each group +/2 SEM; b Imaging enables convenient determination of CSC frequencies; ALL-54
cells were freshly isolated from a mouse spleen, seeded at 106 cells/ml and stimulated in vitro with PBS or TRAIL (1 mg/ml). After 48 hours, cells were
serially diluted based on the cell concentration seeded at the beginning of the experiment and injected into groups of 2–3 mice. After 8 weeks, mice
were imaged and analyzed for leukemic engraftment (defined using signals of legs only, identically as in Figure 3D; engraftment is indicated with
a star); frequency of leukemia initiating cells was calculated out of engraftment rates using Poisson statistics. In all mice, mid-abdominal signals are
unspecific.
doi:10.1371/journal.pone.0052798.g004
Figure 5. Precise quantification of individual treatment effects and monitoring of distinct clinical stages. a Imaging visualizes
treatment-induced cell loss and regrowth; 105 ALL-50 cells/mouse were injected into 10 mice which received a single intraperitoneal dose of Etoposid
(VP-16; 50 mg/kg) in week 6 after tumor cell injection, except the control mouse which was treated with PBS. Animals were imaged before treatment
(pre-treatment) and 4 and 11 days after treatment; shown is one representative mouse; all mice are shown in Supplemental Figure 11; b, cImaging
visualizes different sensitivities of individual samples towards treatment; ALL-199 (16104 cells/mouse) or ALL-4S (56104 cells/mouse) were injected
into 16 mice; mice were randomized in week 4 into one control (n = 4) and two experimental groups (n = 6 each). Control mice received buffer
injection, while the other groups were treated once intraperitoneally with either Etoposid (VP-16; 50 mg/kg) or cyclophosphamide (Cyclo; 150 mg/
kg) as indicated. Mice were imaged directly before and 4 days after treatment; shown are 3 representative mice of each treatment group before and 4
days after treatment (b); shown is the result of quantification of the images; each line represents a single mouse (c); * P,0.05, *** P,0.001, Mann-
Whitney Rank Sum Test; d Imaging visualizes disease stages known from patients; 15 mice were injected with 16106 ALL-199 cells/mouse and
treated once intraperitoneally with Etoposid (VP-16; 50 mg/kg) in week 4; after treatment, mice were imaged three times per week; shown is the
mean +/2 SEM of image quantifications.
doi:10.1371/journal.pone.0052798.g005
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according to published data [19], the growth rate in mice differed
markedly between the samples with sample ALL-177 showing
a slower growth rate compared to most other samples (Supple-
mental Figure 8). Thus, bioluminescence in vivo imaging
represents a useful tool to study inter-sample heterogeneity in
growth kinetics.
To control quality parameters of the model, assay variances
were estimated. Imaging showed a highly reproducible growth of
leukemia in mice with surprisingly low intra- and inter-assay
variances considering that an in vivo model was studied (Figure 3c,
Supplemental Figure 9). Taken together, quantification of in vivo
imaging revealed a strictly logarithmic growth of all individual
leukemias in mice with high reliability and marginal standard
errors.
Visualization of Minimal Disease
Upon anti-leukemia treatment, most patients suffering from
ALL accomplish complete morphological response. Nevertheless,
minimal residual disease (MRD) represents a major clinical threat
as MRD is difficult to treat and often followed by relapse.
Appropriate preclinical models to study MRD are required [20].
To test, whether GLuc-based in vivo imaging could visualize
MRD, its sensitivity was measured. Groups of mice were engrafted
with equal cell numbers of the same sample and were imaged
three times weekly. Upon crossing a clearly defined detection
threshold (signal above 66104 photons per second using defined
criteria, see Methods for details), most mice were sacrificed and
bone marrow and peripheral blood analyzed by flow cytometry,
quantitative real time PCR and immunohistochemistry. All
remaining mice showed constant light increase similar to the
kinetic shown in Figure 2a leading to overt leukemia (Supple-
mental Figure 10).
In all 3 samples tested, imaging was able to detect below 1
leukemia cell in 5,000 mouse bone marrow cells, while in one
sample the detection threshold was even below 1 in 10,000 cells
(Figure 3d and Supplemental Figure 10). Estimating the reported
109 normal bone marrow cells per mouse, imaging allowed the
visualization of less than 100.000 absolute leukemia cells per
mouse. Detection sensitivity directly correlated with the expression
level of the transgenes. At this early stage of first light emission, no
leukemia cells were detected in peripheral blood using either flow
cytometry or quantitative real time PCR. Thus, conventional
readouts in peripheral blood did not allow follow up of leukemia in
living mice at this stage. Instead, GLuc-based bioluminescence
imaging revealed very high sensitivity for detecting human
leukemic cells in mice which now allows studies, e.g., on MRD.
Imaging-based Quantification of Leukemia Initiating Cell
Frequencies
An important current concept in cancer research states that
only cancer stem cells (CSC) are able to maintain tumor growth
and therefore represent the most important targets for anti-cancer
therapy [21]. The limiting dilution transplantation assay (LDTA)
still represents the standard method for studying CSC [22]. LDTA
functionally tests the CSC-defining ability of human tumor cells to
induce tumors in mice. So far, performing LDTAs is hampered by
the requirement of high mouse numbers.
Bioluminescence in vivo imaging allowed observing each group
of mice within the LDTA repetitively over time (Figure 4a).
Thereby, imaging increased the reliability of the measurements.
Furthermore, it clearly visualized the dependence of CSC-
frequency on engraftment time in mice.
Imaging-guided straightforward quantification of CSC-frequen-
cies in LDTA enabled comparing untreated with treated patient-
derived ALL cells using a rational number of mice. As an example,
in vitro treatment of ALL-54 cells with TRAIL (TNF-related,
apoptosis-inducing ligand) prior to transplantation significantly
reduced engraftment of cells in mice (Figure 4b). These data
reproduced our recently published finding that in vitro treatment
with TRAIL reduces engraftment of leukemia cells in mice [23].
Taken together, imaging significantly facilitated performing
LDTAs thus allowing the broader use of this assay in the future,
e.g., to study drug sensitivities of leukemic CSC.
Precise Quantification of Individual Treatment Effects
Treatment failure and relapse represent the most important
challenges in anti-cancer treatment. Sophisticated preclinical
models are required for testing novel therapeutic approaches
addressing these threats in order to prepare their translation into
the clinics.
Individual leukemias were grown until advanced disease (108
photons per second per entire mouse). Imaging allowed starting
treatment in mice with equal tumor burdens, although rarely mice
had to be excluded, as leukemia grew highly homogenously in
mice (compare Supplemental Figure 9). Mice were treated with
conventional cytotoxic drugs by systemic bolus injections in
concentrations modeling drug doses typically applied in patients
[24]. Few days after treatment with an effective drug, light
emission from mice was significantly reduced (Figure 5a). Thereby,
low variances were found within a group of equally treated mice
enabling highly reliable quantification of the therapeutic effects
(Supplemental Figure 11a and 11c). As light emission persisted
after therapy, the single drug application had reduced, but not
eliminated leukemia. In our trials, a single bolus injection reduced
light emission at maximum by 1 order of magnitude suggesting
that at least 10% of tumor cell persist after a single treatment (data
not shown) [25]. The effectiveness of drugs was independent from
the leukemic burden of the mice within the log growth phase.
Therapeutic reduction of leukemia was followed by tumor re-
growth shortly afterwards (Figure 5a).
Imaging results correlated well with data obtained by conven-
tional post-mortem readout parameters in most organs (Supple-
mental Figure 11b and 11d). Treatment nearly eliminated tumor
cells from peripheral blood, while imaging visualized the
remaining tumor burden post treatment (Supplemental Figure
11e). Due to limited sensitivity, conventional measurement in
peripheral blood appears overestimating therapeutic effects,
although this readout was most frequently used for disease
monitoring until today.
In our model, each mouse harbors the leukemia of an individual
patient. Imaging-guided preclinical treatment trials in mice
revealed that individual ALL samples retained individual sensitiv-
ities towards conventional cytotoxic drugs. While the T-ALL
sample ALL-4S was sensitive towards treatment with Cyclophos-
phamide, it was resistant towards Etoposid; in contrast, the B-ALL
sample ALL-199 was resistant towards Cyclophosphamide, but
sensitive towards Etoposid (Figure 5b). Accordingly, treatment
with Cyclophosphamide prolonged survival of ALL-4S, but not of
ALL-199 bearing mice, while Etoposid prolonged survival of ALL-
199, but not of ALL-4S bearing mice (data not shown). Thus,
in vivo imaging was able to visualize specific drug sensitivities of
each individual sample towards a given anti-cancer treatment
shortly after treatment within the preclinical trial.
Most importantly, imaging was able to quantify therapeutic
responses and to visualize tumor regrowth. Due to low assay
variances, imaging allowed distinguishing treatment failure/drug
resistance/progressive disease from partial or complete response
(Figure 5c). As additional advantage, imaging enabled quantifying
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the therapeutic effect already few days after treatment, while
conventional readouts like survival require long incubation
periods.
Taken together, in vivo imaging allowed the rapid, precise and
individual quantification of treatment responses.
Monitoring of Distinct Clinical Stages Upon Treatment in
Mice
The sensitivity of tumor cells towards treatment depends on the
disease stage at which the drug is given [26]. Therefore, preclinical
models are required modelling distinct disease stages including
MRD. Furthermore, time to tumor re-growth/time to tumor
progression/time of progression free survival represents a prognos-
tic parameter for patients, especially in MRD.
After treatment, imaging reliably quantified residual disease.
Short-interval imaging revealed short ‘‘lag phase’’ of no-growth
after a single application for certain, but not all drugs and samples
(Figure 5d). In the later course of the disease, imaging revealed
reappearance of a second logarithmic tumor growth phase
modeling tumor regrowth. Thus, in vivo GLuc-based imaging
allowed the precise preclinical modeling in mice of the complex
clinical course and disease stages known from cancer patients.
Taken together, we have introduced and validated in detail
GLuc-based bioluminescence in vivo imaging in the xenograft
mouse model of individual patient’s ALL. Imaging was easy to
perform and gave rise to highly sensitive and reliable results which
enable the non-invasive accurate and detailed monitoring of
disease progression and treatment responses.
Discussion
GLuc-based bioluminescence in vivo imaging was introduced
and intensively validated as novel readout parameter for the
preclinical model of patient-derived ALL growing in mice. In vivo
imaging allowed performing preclinical trials on a novel level of
accuracy and precision including stage-specific therapy and
quantification of treatment responses. In the future, improvement
of the individualized ALL mouse model by in vivo imaging will
allow performing preclinical trials more exactly and in more detail.
Imaging allowed modeling disease stages in mice which
represent current challenges in the clinics such as minimal residual
disease and tumor regrowth. Imaging was highly sensitive and
continuous and correlated well with post mortem results regarding
tumor distribution. Assay variances were minimal which will
reduce the number of animals required per experiment. In
addition, tumor growth was orthotopic and homogenous and
tumor cells were derived from individual patients with genetically
defined tumors; limiting dilution assays were easily visualized to
study drug sensitivity of leukemia initiating cells. Taken together,
GLuc-based imaging will allow performing high quality and
convenient preclinical treatment trials in the individual mouse
model of ALL in the future.
The most important challenges in cancer treatment represent
treatment failure and relapse. Using in vivo imaging, treatment
failure is easily detectable in the first days after treatment as light
emission continues increasing despite of therapy; short-period
treatment quantification will allow speeding up preclinical
treatment trials. Tumor regrowth is visualized by quantification
of post-therapeutic residual disease followed by monitoring
increase in light emission. Thus, our model is able to exactly
map both important clinical challenges for preclinical trials.
In addition to bioluminescence imaging, fluorescence imaging
represents an interesting alternative with a better anatomical
resolution, especially using near- infrared fluorochromes [12,27].
Even though leukemic cells used in our studies also expressed
GFP, GFP proved non-suitable for in vivo imaging due to the
known high tissue autofluorescence signals emitted at the same
wave length [28]. Fluorescent probes with near-infrared and far-
red light emission have been recently developed which might be
more suitable for small animal imaging [29]. In our hands,
leukemia cells did not express sufficient levels of the mRaspberry
protein (data not shown), which might have been due to reported
cellular toxicity induced by the fluorochrome [30].
Recently, two groups published the use of firefly luciferase for
in vivo imaging of transplanted individual ALLs [31,32]. While
one publication used the method without commenting on
methodological details [31], the second study examined growth
kinetics and showed an imaging-guided treatment trial starting at
mainly invisible leukemia load [30]. The novelty of the present
study lies in (i) the use of GLuc as lighter luciferase; (ii) the detailed
methodological validation of the technique including its sensitivity
allowing in vivo studies on MRD in the future; (iii) the prove that
treatment trials can now be performed at visible leukemic burden
(iv) the ability of imaging to diagnose treatment resistance within
days after treatment allowing secondary interventions; (iv) the
prove that routine clinical outcome parameter can now be
monitored in mice.
The major advantage of using GLuc instead of firefly luciferase
for in vivo imaging is the markedly increased light emission from
superficial organs such as bone marrow in the lower extremities of
mice [18]. Hence, GLuc-based imaging proved superior to firefly
luciferase-based imaging in the context of T-cell imaging [13].
Therefore, we argued that GLuc might be more sensitive
compared to firefly luciferase for imaging of patient-derived ALL
and therefore used GLuc in our experiments.
Leukemic disease serves as a suitable model disease for cancer in
general since leukemia cells are easier in handling compared to
solid tumor cells. Many important research discoveries in cancer
biology were first described in leukemia; for example, oncogenic
mutations are best characterized in acute myeloid leukemia [33]
and; the cancer stem cell concept evolved upon research on
leukemias [34]. Transferring its role from studying tumor biology
to anti-tumor therapy, leukemia might now play a pivotal model
disease for directing anti-cancer treatment towards individualized
and disease stage-specific strategies.
Taken together, GLuc-based in vivo imaging in the individu-
alized preclinical model of ALL enables performing treatment
trials on a novel level of accuracy and precision. It enables
quantifying therapy effects and remaining disease burdens as well
as exact modeling of distinct disease stages. The model facilitates
the detailed preclinical analysis of novel therapies for preparing
their translation into the clinics. The model allows preclinical trials
addressing the most demanding current clinical challenges, such as
treatment failure, resistance in leukemia initiating cells, minimal
residual disease and relapse.
Supporting Information
Supporting Information S1
(PDF)
Acknowledgments
The authors would like to thank Wolfgang Hammerschmidt and Karsten
Spiekermann for scientific discussions, Jean-Pierre Bourquin and Richard
B. Lock for help to establish the animal model, Ulrike Borgmeier, Liliana
Mura and Katharina Michael for excellent technical assistance and the
staff of the animal facility for excellent animal care. We thank Bianka
Ksienzyk and Stefan Bohlander (Laboratory of Leukemia Diagnostics,
In Vivo Imaging of Patients’ ALLs in Mice
PLOS ONE | www.plosone.org 10 December 2012 | Volume 7 | Issue 12 | e52798
University of Munich Hospital, Munich, Germany) for the help with cell
sorting and Claudia Kloss for immunohistochemistry analysis.
Author Contributions
Conceived and designed the experiments: NT IJ MO. Performed the
experiments: VG KS KF EW HE US MH LQ-M. Analyzed the data: NT
CCA VG. Contributed reagents/materials/analysis tools: RJB. Wrote the
paper: NT CCA VG IJ.
References
1. Talmadge JE, Singh RK, Fidler IJ, Raz A (2007) Murine models to evaluate
novel and conventional therapeutic strategies for cancer. Am J Pathol 170: 793–
804.
2. McCormick F (2011) Mutant onco-proteins as drug targets: successes, failures,
and future prospects. Curr Opin Genet Dev 21: 29–33.
3. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational
biomedical research. Nat Rev Immunol 7: 118–130.
4. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of
mutant p53 functional properties on TP53 mutation patterns and tumor
phenotype: lessons from recent developments in the IARC TP53 database. Hum
Mutat 28: 622–629.
5. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS (2011) Mouse models of
advanced spontaneous metastasis for experimental therapeutics. Nat Rev
Cancer 11: 135–141.
6. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, et al. (2004)
Characterization of childhood acute lymphoblastic leukemia xenograft models
for the preclinical evaluation of new therapies. Blood 103: 3905–3914.
7. Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, et al. (1989) A
model of human acute lymphoblastic leukemia in immune-deficient SCID mice.
Science 246: 1597–1600.
8. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, et al. (2011) Evolution
of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469:
362–367.
9. Schmitz M, Breithaupt P, Scheidegger N, Cario G, Bonapace L, et al. (2011)
Xenografts of highly resistant leukemia recapitulate the clonal composition of the
leukemogenic compartment. Blood;118: 1854–1864.
10. Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, et al. (2008) An update on
the xenograft and mouse models suitable for investigating new therapeutic
compounds for the treatment of B-cell malignancies. Curr Pharm Des 14: 2023–
2039.
11. O’Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT (2010)
Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol
220: 317–327.
12. Lyons SK (2005) Advances in imaging mouse tumour models in vivo. J Pathol
205: 194–205.
13. Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, et al. (2009) Sensitive in vivo
imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat
Med 15: 338–344.
14. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-
generation lentivirus vector with a conditional packaging system. J Virol 72:
8463–8471.
15. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, et al. (2008)
Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell
lymphoma has minimal effects on cell survival and reveals a regulatory circuit
with cyclin D2. Leukemia 22: 2097–2105.
16. Ehrhardt H, Hofig I, Wachter F, Obexer P, Fulda S, et al. (2012) NOXA as
critical mediator for drug combinations in polychemotherapy. Cell Death Dis 3:
e327.
17. Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, et al. (2011)
Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel,
mechanism-based application schedule. Blood 118: 6123–6131.
18. Inoue Y, Sheng F, Kiryu S, Watanabe M, Ratanakanit H, et al. (2011) Gaussia
luciferase for bioluminescence tumor monitoring in comparison with firefly
luciferase. Mol Imaging 10: 377–385.
19. Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, et al. (2011)
Early relapse in all is identified by time to leukemia in NOD/SCID mice and is
characterized by a gene signature involving survival pathways. Cancer Cell 19:
206–217.
20. Bottcher S, Ritgen M, Dreger P (2011) Allogeneic stem cell transplantation for
chronic lymphocytic leukemia: lessons to be learned from minimal residual
disease studies. Blood Rev 25: 91–6.
21. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer
stem cells–perspectives on current status and future directions: AACR Workshop
on cancer stem cells. Cancer Res 66: 9339–9344.
22. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, et al. (2009)
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia
23: 25–42.
23. Castro AC, Terziyska N, Grunert M, Gundisch S, Graubner U, et al. (2012)
Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia
xenografts are sensitive toward TRAIL. Blood 119: 4224–4227.
24. Ehrhardt H, Wachter F, Maurer M, Stahnke K, Jeremias I (2011) Important
Role of Caspase-8 for Chemosensitivity of ALL Cells. Clin Cancer Res 17:
7605–7613.
25. Dy GK, Adjei AA (2008) Systemic cancer therapy: evolution over the last 60
years. Cancer 113: 1857–1887.
26. Francia G, Man S, Lee CJ, Lee CR, Xu P, et al. (2009) Comparative impact of
trastuzumab and cyclophosphamide on HER-2-positive human breast cancer
xenografts. Clin Cancer Res 15: 6358–6366.
27. Ntziachristos V, Ripoll J, Wang LV, Weissleder R (2005) Looking and listening
to light: the evolution of whole-body photonic imaging. Nat Biotechnol 23: 313–
320.
28. Troy T, Jekic-McMullen D, Sambucetti L, Rice B (2004) Quantitative
comparison of the sensitivity of detection of fluorescent and bioluminescent
reporters in animal models. Mol Imaging 3: 9–23.
29. Shcherbo D, Merzlyak EM, Chepurnykh TV, Fradkov AF, Ermakova GV, et al.
(2007) Bright far-red fluorescent protein for whole-body imaging. Nat Methods
4: 741–746.
30. Shaner NC, Steinbach PA, Tsien RY (2005) A guide to choosing fluorescent
proteins. Nat Methods 2: 905–909.
31. Barrett DM, Seif AE, Carpenito C, Teachey DT, Fish JD, et al. (2011)
Noninvasive bioluminescent imaging of primary patient acute lymphoblastic
leukemia: a strategy for preclinical modeling. Blood 118: e112-e117.
32. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, et al. (2011) BCL6 enables
Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.
Nature 473: 384–8.
33. Marcucci G, Haferlach T, Dohner H (2011) Molecular genetics of adult acute
myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 10;29:
475–486.
34. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112: 4793–
4807.
In Vivo Imaging of Patients’ ALLs in Mice
PLOS ONE | www.plosone.org 11 December 2012 | Volume 7 | Issue 12 | e52798
